Oncocentro APYS - Viña del Mar
Oncocentro APYS - Viña del Mar
Avenida La Marina 1702, Viña del Mar, Valparaíso
Select an option
I am a doctor
I am a sponsor
Our team
Medical staff
Valentina Vargas Guzman
Manuel Enrique Novajas Balboa
Felipe Saavedra
Florencia Letelier
Jorge Javier Miranda Madariaga
Macarena Antonia Carcamo Medina
Eunice Jerez Rivera
Yenifer Donoso Maya
Magdalena Reyes
Luis Roca
Macarenna Osorio
Alejandro Andrés Acevedo
Claudia Jimenez
Open studies
Lung cancer
Double-blind Study to Evaluate the PK, Efficacy, Safety and Immunogenicity of MB12 Versus Keytruda® in Stage IV NSCLC - MB12-C-01-22 - Laboratorio Elea Phoenix S.A.See more
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) - MK-2870-004 - Merck Sharp & Dohme LLCSee more
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) - INTerpath-002 - Merck Sharp & Dohme LLCSee more
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) - MK-2870-019 - Merck Sharp & Dohme LLCSee more
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] - MK-2870-023 - Merck Sharp & Dohme LLCSee more
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% - RELATIVITY1093 - Bristol-Myers SquibbSee more
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) - INTerpath-009 - Merck Sharp & Dohme LLCSee more
Endometrial Cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) - TroFuse-033 - Merck Sharp & Dohme LLCSee more
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) - OMAHA-015 - Merck Sharp & Dohme LLCSee more
Prostate cancer
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. - MEVPRO-2 - PfizerSee more
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) - MK-2400-01A/IDeate-Prostate02 - Merck Sharp & Dohme LLCSee more
Bladder Cancer
A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) - Merck Sharp & Dohme LLCSee more
Breast Cancer
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) - OMAHA-015 - Merck Sharp & Dohme LLCSee more
Cervical cancer
A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) - MK-2870-020 - GOG FoundationSee more
Colorectal cancer
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer - MOUNTAINEER-03 - Seagen Inc.See more
Heart failure
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity - MARITIME-HF - AmgenSee more
Lupus
A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus - AMETHYST - BiogenSee more
Obesity
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity - MARITIME-HF - AmgenSee more
Ovarian cancer
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) - OMAHA-015 - Merck Sharp & Dohme LLCSee more
Pulmonary fibrosis
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis - ALOFT-PPF - Bristol-Myers SquibbSee more
Solid tumors
A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) - OMAHA-015 - Merck Sharp & Dohme LLCSee more
